Calithera Biosciences, Inc. (CALA) Reaches $5.12 After 6.00% Up Move; Herzfeld Caribbean Basin Fund (CUBA) Has 1 Sentiment

June 13, 2018 - By Peter Erickson

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Herzfeld Caribbean Basin Fund Inc (CUBA) investors sentiment decreased to 1 in Q1 2018. It’s down -1.40, from 2.4 in 2017Q4. The ratio is negative, as 8 investment professionals opened new and increased stock positions, while 8 sold and reduced their equity positions in Herzfeld Caribbean Basin Fund Inc. The investment professionals in our database now possess: 2.16 million shares, up from 2.13 million shares in 2017Q4. Also, the number of investment professionals holding Herzfeld Caribbean Basin Fund Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 3 Reduced: 5 Increased: 5 New Position: 3.

The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) is a huge mover today! The stock increased 8.41% or $0.4 during the last trading session, reaching $5.12. About 369,148 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 65.69% since June 13, 2017 and is downtrending. It has underperformed by 78.26% the S&P500. Some Historical CALA News: ; 03/05/2018 – Calithera Biosciences Presenting at Conference Jun 2; 18/04/2018 – Calithera Biosciences: Designation Granted for Treatment of Patients With Advanced Renal Cell Carcinoma; 10/05/2018 – Calithera Biosciences Initiated Randomized Phase 2 CANTATA Trial; 13/04/2018 – Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018; 27/03/2018 – Calithera Biosciences Presenting at Conference Tomorrow; 18/04/2018 – Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma; 13/04/2018 – Calithera Biosciences Presenting at Conference Apr 16; 18/04/2018 – CALITHERA’S CB-839 WITH CABOZANTINIB GRANTED FAST TRACK STATUS; 18/04/2018 – Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of; 22/04/2018 – DJ Calithera Biosciences Inc, Inst Holders, 1Q 2018 (CALA)The move comes after 5 months positive chart setup for the $183.61M company. It was reported on Jun, 13 by Barchart.com. We have $5.43 PT which if reached, will make NASDAQ:CALA worth $11.02 million more.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on August, 14. They expect $-0.33 EPS, down 120.00% or $0.18 from last year’s $-0.15 per share. After $-0.37 actual EPS reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts -10.81% EPS growth.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was initiated by Citigroup with “Sell” on Tuesday, October 25. Citigroup upgraded the stock to “Neutral” rating in Tuesday, January 24 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, June 12. The rating was initiated by Citigroup with “Buy” on Friday, July 24. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock has “Buy” rating by H.C. Wainwright on Thursday, January 5. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, March 28 report. Citigroup upgraded the shares of CALA in report on Friday, February 16 to “Buy” rating.

Investors sentiment decreased to 0.91 in 2018 Q1. Its down 1.29, from 2.2 in 2017Q4. It fall, as 16 investors sold Calithera Biosciences, Inc. shares while 29 reduced holdings. 10 funds opened positions while 31 raised stakes. 21.05 million shares or 12.94% less from 24.18 million shares in 2017Q4 were reported. Secor Capital Advisors Limited Partnership holds 0.05% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 91,577 shares. Dimensional Fund L P reported 472,394 shares or 0% of all its holdings. Barclays Plc accumulated 18,818 shares. 2,800 were accumulated by Macquarie Limited. Wells Fargo & Mn owns 65,566 shares or 0% of their US portfolio. Iconiq Cap Lc reported 23,222 shares. Adage Capital Partners Group Inc Ltd has 0.01% invested in Calithera Biosciences, Inc. (NASDAQ:CALA). American Intl Group stated it has 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Jpmorgan Chase has 6,167 shares for 0% of their portfolio. Federated Inc Pa reported 0.03% stake. Century owns 796,726 shares. Schwab Charles Investment Mngmt holds 125,935 shares. Ameritas Invest Partners reported 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Swiss Comml Bank owns 45,300 shares or 0% of their US portfolio. Fred Alger Management invested 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA).

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $183.61 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

More important recent Calithera Biosciences, Inc. (NASDAQ:CALA) news were published by: Nasdaq.com which released: “Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June” on June 06, 2018, also Nasdaq.com published article titled: “Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at …”, Nasdaq.com published: “Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National …” on May 16, 2018. More interesting news about Calithera Biosciences, Inc. (NASDAQ:CALA) was released by: Benzinga.com and their article: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018.

The stock increased 0.60% or $0.04 during the last trading session, reaching $6.75. About 9,392 shares traded. The Herzfeld Caribbean Basin Fund Inc. (CUBA) has declined 3.69% since June 13, 2017 and is downtrending. It has underperformed by 16.26% the S&P500.

Since January 1, 0001, it had 9 insider purchases, and 0 insider sales for $484,673 activity.

More news for The Herzfeld Caribbean Basin Fund Inc. (NASDAQ:CUBA) were recently published by: Equitiesfocus.com, which released: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Herzfeld Caribbean Basin Fund, Inc. common stock …” on June 06, 2018. Equitiesfocus.com‘s article titled: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Herzfeld Caribbean Basin Fund (CUBA) Stock Price” and published on May 30, 2018 is yet another important article.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>